Comparative study between Metformin, Glibenclamide and their combination in newly diagnosed diabetic (type II) patients in Hawler City

S, D.; Sazan,; Kassim,; J.S,; N.H,; Ansam,

	Comparative study between Metformin, Glibenclamide and their combination in newly diagnosed diabetic (type II) patients in Hawler City
Al-Mustansiriyah Journal for Pharmaceutical Sciences
Article 1, Volume 12, Issue 2, 2012, Pages 61-74
Authors
D. S; ; ; ; ;
Abstract
Abstract: Type 2 diabetes mellitus is a complex progressive disorder characterized by impaired insulin sensitivity, reduced insulin secretion and progressive failure of pancreatic β – cells. Type 2 diabetes therapies are initiated with lifestyle changes (diet, exercise) and pharmacologic agents, including oral antidiabetic drug, among them: sulphonylurea (glibenclamide), Biguanide (metformin) and combination of them. The objective of this study is to compare the efficacy of the drugs, both as monotherapy and in combination, and discussed evidence – based treatment. forty patients with (FPG of 167.9±3.5mg/dl; PPG of 276.3±5.4mg/dl; HbAlcof 8.1±0.2%) were received metformin (500mg tid), and 15 patients with (FPG of 165.1±4.3; PPG of 273.6±5.5; HbAlc of 7.9±0.2) were received glibenclamide (5mg once daily) monotherapy, 35 patients with (FPG of 179±4.1; PPG of 304.4±5.6; HbAlc of 7.9±0.1) were received glibenclamide/metformin (2.5mg/500mg bid) as combination therapy. Blood samples were withdrawn from the patients at pretreatment, then monthly for three months. After 3 months of treatment, patients who received glibenclamide/metformin combination (2.5/500mg) had greater reductions in FPG, PPG and HbAlc (-70.6mg/dl, -

Statistics Article View: 99 PDF Download: 55